JP2020505335A5 - - Google Patents

Download PDF

Info

Publication number
JP2020505335A5
JP2020505335A5 JP2019537216A JP2019537216A JP2020505335A5 JP 2020505335 A5 JP2020505335 A5 JP 2020505335A5 JP 2019537216 A JP2019537216 A JP 2019537216A JP 2019537216 A JP2019537216 A JP 2019537216A JP 2020505335 A5 JP2020505335 A5 JP 2020505335A5
Authority
JP
Japan
Prior art keywords
formula
compound
alkyl
acceptable salt
physiologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019537216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505335A (ja
JP7728634B2 (ja
Filing date
Publication date
Priority claimed from GBGB1700259.3A external-priority patent/GB201700259D0/en
Priority claimed from GBGB1716047.4A external-priority patent/GB201716047D0/en
Application filed filed Critical
Priority claimed from PCT/GB2018/050021 external-priority patent/WO2018127702A1/en
Publication of JP2020505335A publication Critical patent/JP2020505335A/ja
Publication of JP2020505335A5 publication Critical patent/JP2020505335A5/ja
Priority to JP2023061291A priority Critical patent/JP2023098938A/ja
Application granted granted Critical
Publication of JP7728634B2 publication Critical patent/JP7728634B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019537216A 2017-01-06 2018-01-05 ウイルス Active JP7728634B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023061291A JP2023098938A (ja) 2017-01-06 2023-04-05 ウイルス

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1700259.3 2017-01-06
GBGB1700259.3A GB201700259D0 (en) 2017-01-06 2017-01-06 Virus
GB1716047.4 2017-10-02
GBGB1716047.4A GB201716047D0 (en) 2017-10-02 2017-10-02 Virus
PCT/GB2018/050021 WO2018127702A1 (en) 2017-01-06 2018-01-05 Virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023061291A Division JP2023098938A (ja) 2017-01-06 2023-04-05 ウイルス

Publications (3)

Publication Number Publication Date
JP2020505335A JP2020505335A (ja) 2020-02-20
JP2020505335A5 true JP2020505335A5 (cg-RX-API-DMAC7.html) 2021-02-12
JP7728634B2 JP7728634B2 (ja) 2025-08-25

Family

ID=61022367

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019537216A Active JP7728634B2 (ja) 2017-01-06 2018-01-05 ウイルス
JP2023061291A Pending JP2023098938A (ja) 2017-01-06 2023-04-05 ウイルス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023061291A Pending JP2023098938A (ja) 2017-01-06 2023-04-05 ウイルス

Country Status (11)

Country Link
US (2) US12016949B2 (cg-RX-API-DMAC7.html)
EP (1) EP3565591A1 (cg-RX-API-DMAC7.html)
JP (2) JP7728634B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190104051A (cg-RX-API-DMAC7.html)
CN (1) CN110621350A (cg-RX-API-DMAC7.html)
AU (1) AU2018206304A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019014004A2 (cg-RX-API-DMAC7.html)
CA (1) CA3048313A1 (cg-RX-API-DMAC7.html)
IL (1) IL267785A (cg-RX-API-DMAC7.html)
MX (1) MX2019008105A (cg-RX-API-DMAC7.html)
WO (1) WO2018127702A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5869553B2 (ja) 2010-03-31 2016-02-24 スタビリテック リミテッド ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
WO2018127702A1 (en) * 2017-01-06 2018-07-12 Stabilitech Biopharma Ltd Virus
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
US20200061210A1 (en) * 2018-08-27 2020-02-27 BioViva USA, Inc. Novel method for gene therapy using intranasal administration of genetically modified viral vectors
JP7436274B2 (ja) * 2020-04-16 2024-02-21 デンカ株式会社 アデノウイルスの免疫測定方法及び免疫測定器具
GB202104320D0 (en) 2021-03-26 2021-05-12 Iosbio Ltd Enhancement of viral titres
CN113880723A (zh) * 2021-11-15 2022-01-04 河南海尔希生物科技有限公司 一种盐酸甜菜碱的制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296130A (en) 1979-08-30 1981-10-20 Herschler R J Methylsulfonylmethane and methods of use
AU719950B2 (en) * 1995-06-07 2000-05-18 Yale University Oral delivery of adeno-associated viral vectors
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
CA2364417C (en) 1999-02-19 2013-11-05 Matthew John During Peroral gene therapy of diabetes and obesity
CN102151337B (zh) 2000-03-13 2014-03-12 恩根尼公司 调节消化道蛋白表达的组合物和方法
US7226779B2 (en) 2001-01-30 2007-06-05 The United States Of America As Represented By The Department Of Health And Human Services Hybrid adenoviral vector
US20030003583A1 (en) 2001-06-08 2003-01-02 Raphael Hirsch Regulation of transgene expression following AAV transduction
WO2003039593A1 (en) 2001-11-08 2003-05-15 Akzo Nobel N.V. Fowl adenovirus vaccine
JP4888876B2 (ja) 2003-06-13 2012-02-29 田平 武 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
US20060140908A1 (en) * 2003-06-18 2006-06-29 Ertl Hildegund C J Methods for inducing an immune response via oral administration of an adenovirus
DK2002003T3 (en) 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA
EP2324850A1 (en) 2005-10-04 2011-05-25 Alk-Abelló A/S Solid vaccine formulation
PT1996238T (pt) * 2006-02-28 2016-07-11 Vaxart Inc Vetores adenovíricos quiméricos e arncd como agonista de tlr3
WO2010146598A2 (en) 2008-11-07 2010-12-23 Serum Institute Of India Ltd. Stable, dried rotavirus vaccine, compositions and process for preparation thereof
BRPI0924123B8 (pt) 2008-12-22 2021-05-25 Oncos Therapeutics Oy vetores adenovirais oncolíticos, usos dos mesmos, composição farmacêutica e método para produzir gmcsf em uma célula in vitro
WO2011034950A1 (en) 2009-09-16 2011-03-24 Vaxart, Inc. Immunization strategy to prevent h1n1 infection
WO2011121306A1 (en) * 2010-03-31 2011-10-06 Stabilitech Ltd. Stabilisation of viral particles
JP5869553B2 (ja) * 2010-03-31 2016-02-24 スタビリテック リミテッド ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤
AU2011306846B2 (en) 2010-09-24 2015-05-14 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
CA2828248A1 (en) * 2011-02-24 2012-08-30 Paxvax, Inc. Formulations useful for spray drying vaccines
GB201117233D0 (en) * 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
KR101989171B1 (ko) * 2012-10-17 2019-06-14 바스큘라 바이오제닉스 리미티드 아데노바이러스를 사용하는 치료 방법
EP3107568B1 (en) * 2014-02-20 2024-03-27 Vaxart, Inc. Formulations for small intestinal delivery
JP2017507672A (ja) * 2014-02-28 2017-03-23 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. 複製型組み換えアデノウイルスベクター、組成物およびこれらの使用方法
GB201406569D0 (en) * 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
KR102678401B1 (ko) * 2015-06-12 2024-06-26 박사르트, 인크. Rsv 및 노로바이러스 항원들의 소장 내의 전달을 위한 제형들
WO2018127702A1 (en) * 2017-01-06 2018-07-12 Stabilitech Biopharma Ltd Virus
GB2562241B (en) * 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
CN108795984A (zh) * 2018-07-05 2018-11-13 天津医科大学 一种利用腺病毒载体构建小肠降表达胰岛素大鼠模型的方法

Similar Documents

Publication Publication Date Title
ES2584430T3 (es) Estrategias para prevenir y/o tratar las respuestas inmunitarias a los alofactores solubles
TWI693219B (zh) Hiv蛋白殼抑制劑之膽鹼鹽形式
AP408A (en) Vaccine composition containing adjuvants.
ES2333282T3 (es) Complejos vesiculares y metodos para la preparacion y utilizacion de los mismos.
Mazumdar et al. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice
ES2981241T3 (es) Formas cristalinas de tenofovir alafenamida
KR101747987B1 (ko) 단순 헤르페스 바이러스 백신
WO2020063370A2 (zh) 免疫组合物及其制备方法与应用
JP7530991B2 (ja) ワクチンアジュバントとしてのハロゲン化キサンテン
TW201446263A (zh) 治療或預防人類免疫缺乏病毒感染之組合物及方法
CA3048313A1 (en) Virus
JP2017532316A5 (cg-RX-API-DMAC7.html)
JP2023501869A (ja) 重症急性呼吸器症候群ウイルスSARS-CoV-2に対する特異的免疫を誘導するための液体形態(変異型)の薬剤
Domingo et al. Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D
Wang et al. Protection against genotype VII Newcastle disease virus challenge by a minicircle DNA vaccine coexpressing F protein and chicken IL-18 adjuvant
JP2002523458A5 (cg-RX-API-DMAC7.html)
EP4010477A1 (en) Agent for inducing specific immunity against sars-cov-2
Cooper et al. Epitope mapping of full-length glycoprotein D from HSV-2 reveals a novel CD4+ CTL epitope located at the transmembrane-cytoplasmic junction
US20200347036A1 (en) Solid forms of an hiv protease inhibitor
WO1998046263A1 (en) Saponin adjuvants in combination with dna vaccination
EP4702988A1 (en) Combination product for the treatment of leishmaniasis
RU2678981C2 (ru) Композиция от бешенства, содержащая адъювант pika
KR100825984B1 (ko) 조사된 인간 b형 간염 표면 항원을 발현하는 암세포를이용하여 종양을 치료하는 방법 및 상기 암세포를 포함하는종양치료용 약학적 조성물
RU2023131792A (ru) Композиции против коронавируса и гриппа и способы их использования
JPS6136728B2 (cg-RX-API-DMAC7.html)